Ionis Pharmaceuticals IONS Royalty Payments
Royalty Payments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:RoyaltyPayments.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's royalty payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's royalty payments?
- Ionis Pharmaceuticals (IONS) reported royalty payments of $11.69M in Q1 2026.
- How has Ionis Pharmaceuticals's royalty payments changed year-over-year?
- Ionis Pharmaceuticals's royalty payments decreased by 9.3% year-over-year, from $12.89M to $11.69M.
- What does royalty payments mean?
- Payments made to others for the right to use their technology or patents.
- How do you interpret royalty payments?
- Increasing payments may signal successful product commercialization but also indicate a reliance on external intellectual property.
- How does royalty payments compare across companies?
- Highly specific to the pharmaceutical industry where licensing and collaborative development are common.